

4. (Amended) An immunomodulator according to claim 1, wherein the T-cell binding site of the antigen-presenting cell (APC) targeting molecule has been deleted.

5. (Amended) An immunomodulator according to claim 1, wherein the antigen-presenting cell (APC) targeting molecule is derived from *Staphylococcus aureus* and/or *Streptococcus pyogenes*.

8. (Amended) An immunomodulator according to claim 6, wherein the antigen-presenting cell (APC) targeting molecule is designated SPEC-Y15A R181Q.

9. (Amended) An immunomodulator according to claim 6, wherein the antigen-presenting cell (APC) targeting molecule is designated SPEC-Y15A.C27S.N79C.R181Q.

10. (Amended) An immunomodulator according to claim 1, wherein the antigen-presenting cell (APC) targeting molecule is coupled reversibly to an immunomodulatory antigen.

11. (Amended) An immunomodulator according to claim 1, wherein the immunomodulatory antigen is a protein, a polypeptide and/or a peptide.

12. (Amended) An immunomodulator according to claim 1, wherein the immunomodulatory antigen is a nucleic acid.

13. (Amended) An immunomodulator according to claim 1, wherein the immunomodulatory antigen is non-immunogenic when not coupled to the antigen-presenting cell (APC) targeting molecule.

14. (Amended) An immunomodulator according to claim 4, wherein the antigen-presenting cell (APC) targeting molecule is SPEC (-20-90).

15. (Amended) Pharmaceutical composition comprising an immunomodulator according to claim 1 and a pharmaceutically acceptable carrier, adjuvant, excipient and/or solvent.

16. (Amended) Vaccine comprising an immunomodulator according to claim 1.

A3
cancel
17. (Amended) Method of therapeutic or prophylactic treatment of a disorder which requires the induction or stimulation of the immune system, comprising the administration to a subject requiring such treatment of an immunomodulator according to claim 1.

A4
23. (Amended) A method according to claim 21, wherein the antigen-presenting cell (APC) targeting molecule is SPE-C Y15A R181Q.

24. (Amended) A method according to claim 21, wherein the antigen-presenting cell (APC) targeting molecule is designated SPEC-Y15A.C27S.N79C.R181Q.

25. (Amended) A method according to claim 21, wherein the antigen-presenting cell (APC) targeting molecule is SPEC (-20-90).

A5
30. (Amended) A method according to claim 26, wherein the antigen-presenting cell (APC) targeting molecule is derived from *Staphylococcus aureus* and/or *Streptococcus pyogenes*.

A6
36. (Amended) A method according to claim 26, wherein the antigen-presenting- cell (APC) targeting molecule is coupled reversibly to said compound.

37. (Amended) A method according to claim 26, wherein the compound is selected from the group consisting of a protein, a polypeptide and/or a peptide, a carbohydrate or a nucleic acid.

Applicant : John David [REDACTED] et al
Serial No. :
Filed : December 3, 2001
Page : 4

Attorney's Do [REDACTED] No.: 12669-002001 / 30072UPS00

AG
Acoral

38. (Amended) A method according to claim 26, wherein the compound is non-immunogenic when not coupled to the antigen-presenting cell (APC) targeting molecule. ~~14~~

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100